trial

A Study in Schizophrenic Patients

NCTId NCT01125358
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 82 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2012-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
82 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2010-05
Primary completion
2012-09
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
Pomaglumetad

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

22 total
Aichi, JapanKanagawa, JapanKumamoto, JapanKyoto, JapanNagano, JapanNagasaki, JapanNara, JapanOsaka, JapanSaga, JapanTokyo, JapanToyama, JapanYamaguchi, Japan

Linked catalysts

1
A Study in Schizophrenic Patients — primary completion2012-09

Facts & assertions

4 sourced
Enrollment
82
Phase
PHASE2
Primary Completion Date
2012-09
Status
TERMINATED
relationships
The graph out of here
drug
Pomaglumetad
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person